Q3 Revenue Jumps 64% to $340.5M as Lifyorli Launch Accelerates; Guidance Reiterated
CORT has more than doubled off its 52-week low of $28.66.
Summary
Corcept delivered a big step-up in Q3: revenue of $340.5M versus $256.1M in Q2, with net income of $126.8M versus $43.0M the prior quarter and EPS of $1.01. Lifyorli, launched April 1st, brought in $91.4M, up 92% sequentially, and management says more than 2,300 patients and 1,700 prescribers are already on board. Korlym and authorized generic revenue rose 19% to $249.1M, and the company reiterated 2026 revenue guidance of $1.1-$1.2 billion. Cash and investments grew to $662.3M from $544.6M at June 30, even after $43.7M of buybacks. The pipeline added two items: MONARCH MASH data showed 19% fibrosis improvement at 48 weeks with a higher-dose Phase 2 starting soon, and DAZALS ALS exploratory analyses showed an 84% reduction in risk of death in year one, with a Phase 3 planned for next year. The nearest hard catalyst is the FDA's December 17, 2026 PDUFA decision on relacorilant for Cushing's syndrome.
At the time of this announcement, CORT was trading at $81.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $28.66 to $126.38. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.